DarioHealth Corp.

NASDAQ:DRIO

Medical - Diagnostics & Research

Healthcare
$5.13 -1.68%

-$0.12 today

Market cap
$50.27M
Beta
1.08
P/E (TTM)
5.5
EPS (TTM)
$1.26
52W Low $5.94High $17.74

Volume 0.01M

Average 0.01M

DRIO Income Before Tax

Profit after all operating and non-operating items but before income tax.

DarioHealth Corp.NASDAQ: DRIO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$8.19M, compared with -$9.21M a year earlier. Trailing-twelve-month income before tax was $62.75M.

Context

  • Income before tax amounted to 186.1% of revenue in FY2025, up 21.2 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$8.19M or moves back toward the trailing-twelve-month quarterly average of $15.69M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.19M-108.7% QoQ
Last fiscal yearDec 2025
-$41.61M+6.7% YoY
LTMMar 2026
$62.75M+240.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.0%——
1 year+6.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(41.61M) USD
Year-over-year change
+6.7%

Income Before Tax vs competitors

How DRIO compares with its peers on the latest reported figures

  • DRIO's LTM Mar 2026 income before tax of $62.75M is the highest of the 11 companies compared; the peer median is -$100.63M.
  • Its year-over-year change of +240.6% is the highest of 11, against a peer median of +11.7%.
  • Income before tax amounts to 296.1% of revenue for DRIO, versus a peer median of 61.1%.
DRIO Competitors Peer median
Income Before Tax for DRIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DRIODarioHealth Corp.LTM Mar 2026$62.75M +240.6%—296.1%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$7.23M +204.6%-10.3%74.1%
INNVInnovAge Holding Corp.LTM Mar 2026-$20.46M +33.5%—2.2%
OFIXOrthofix Medical Inc.LTM Mar 2026-$59.51M +57.7%—7.2%
AVNSAvanos Medical, Inc.LTM Mar 2026-$68.3M +82.7%—9.5%
FLGTFulgent Genetics, Inc.LTM Mar 2026-$82.91M -67.5%—25.9%
ABSIAbsci CorporationLTM Mar 2026-$118.35M -10.2%—6445.8%
PACBPacific Biosciences of California, Inc.LTM Mar 2026-$127.77M +80.6%—79.8%
VSTMVerastem, Inc.LTM Mar 2026-$193.96M -30.4%—391.2%
RGNXREGENXBIO Inc.LTM Mar 2026-$290.01M -83.9%—330.2%
MYGNMyriad Genetics, Inc.LTM Mar 2026-$399.8M -215.1%—48.2%
Peer median (excluding DRIO) -$100.63M+11.7%-10.3%61.1%

Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.51M27.66M20.35M27.04M22.36M
Cost of Revenue12.44M18M14.37M13.77M9.69M
Gross Profit8.07M9.66M5.98M13.27M12.67M
Gross Margin39.3%34.9%29.4%49.1%56.6%
Research & Development17.22M19.65M20.25M24.18M13.79M
Selling, General & Admin62.36M46.82M41.8M46.83M35.53M
Operating Expenses84.56M66.47M62.17M71.01M49.32M
Depreciation & Amortization4.46M4.72M4.99M7.43M3.56M
EBITDA(70.02M)(55.6M)(54.38M)(37.08M)(34.69M)
EBITDA Margin-341.3%-201.0%-267.2%-137.1%-155.2%
Operating Income(76.49M)(56.81M)(56.19M)(57.74M)(36.66M)
Operating Margin-372.9%-205.4%-276.1%-213.6%-163.9%
Interest Income44K506K1.87M1.12M943K
Interest Expense84K2.68M645K96K3.36M
Other Income / Expenses(235K)(5.38M)(3.17M)13.15M(4.95M)
Income Before Tax(76.73M)(62.19M)(59.36M)(44.6M)(41.61M)
Pre-Tax Margin-374.1%-224.9%-291.7%-164.9%-186.1%
Income Tax Expense32K4K64K(1.85M)105K
Net Income(76.76M)(62.19M)(59.43M)(42.75M)(41.71M)
Net Margin-374.2%-224.9%-292.0%-158.1%-186.6%
EPS (Basic)(4.63)(2.63)(1.93)(0.74)1.24
EPS (Diluted)(4.63)(2.63)(1.93)(0.74)1.24
Weighted Avg Shares16.59M23.64M28.37M40.42M49.63M
Weighted Avg Shares (Diluted)16.59M23.64M28.37M40.42M49.63M

DarioHealth Corp.

NASDAQ:DRIO

Intrinsic Alpha fair value

Locked

Current Price

$5.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.